Abhijeet Basu, MD
Cardiovascular Disease · Houston, TXNPI 1902853666
Payments from drug & device makers
Across 505 payments — averaging $30.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$3K
- Biotronik Inc.$2K
- Pfizer$868
- Novartis$762
- E.r. Squibb & Sons, L.L.C.$720
- plus $4K from 23 others
What the payments were for
- Food & beverage$15,491100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 117 | $4,963 |
| Medtronic(2 entities) | 23 | $2,533 |
| Biotronik Inc. | 25 | $2,069 |
| Pfizer | 64 | $868 |
| Novartis | 69 | $762 |
| E.r. Squibb & Sons, L.L.C. | 49 | $720 |
| Johnson & Johnson(2 entities) | 58 | $639 |
| Abiomed | 4 | $511 |
| Amgen | 27 | $501 |
| Boston Scientific | 9 | $425 |
| AstraZeneca | 8 | $207 |
| Esperion Therapeutics, Inc. | 12 | $197 |
| Edwards Lifesciences | 2 | $156 |
| Acutus Medical, Inc. | 1 | $135 |
| Motiva USA, LLC | 1 | $121 |
| Tactile Systems Technology Inc | 5 | $108 |
| Merck | 5 | $92 |
| Novo Nordisk | 4 | $87 |
| Sanofi-aventis U.S. LLC | 5 | $79 |
| Heartflow, Inc. | 4 | $58 |
| Boehringer Ingelheim | 3 | $52 |
| Impulse Dynamics (USA) Inc. | 2 | $45 |
| Astellas Pharma US Inc | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Altathera Pharmaceuticals LLC | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Biosense Webster, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$1,257
- Confirm Rx$964
- RESOLUTE ONYX$526
- Impella$511
- BioMonitor$451
- Edora$301
- Acticor$301
- Solia$301
- Rivacor$301
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$266
- CardioMEMS HF System$161
- ONYX FRONTIER$156
- CARDIOMEMS$146
- Assurity Pacemaker$144
- UNIFY ASSURA$133
- HawkOne$125
- Motiva Implant Matrix$121
- GENERAL - THERAPIES$117
- Watchman$113
- Repatha$113
How this compares
$15,491 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 518 | $532,442 |
| Repatha SureclickEvolocumab | 192 | $160,496 |
| XareltoRivaroxaban | 134 | $146,192 |
| EntrestoSacubitril/Valsartan | 53 | $56,443 |
| MultaqDronedarone Hcl | 31 | $53,785 |
| BrilintaTicagrelor | 30 | $26,448 |
| OzempicSemaglutide | 18 | $22,044 |
| Praluent PenAlirocumab | 26 | $15,977 |
| FarxigaDapagliflozin Propanediol | 11 | $14,823 |
| JardianceEmpagliflozin | 11 | $11,889 |
| Propafenone Hcl ErPropafenone Hcl | 57 | $7,614 |
| Benicar HctOlmesartan/Hydrochlorothiazide | 13 | $5,466 |
| Metoprolol Succinate | 267 | $4,660 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 175 | $4,581 |
| Valsartan | 142 | $3,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $868 | $532,442518 claims |
| Johnson & JohnsonXarelto | $639 | $146,192134 claims |
| NovartisEntresto | $762 | $56,44353 claims |
| Sanofi-aventis U.S. LLCMultaq | $79 | $53,78531 claims |
| AstraZenecaBrilinta, Farxiga | $207 | $41,27141 claims |
| Novo NordiskOzempic | $87 | $22,04418 claims |
| Boehringer IngelheimJardiance | $52 | $11,88911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.